|
Market Cap (3-Jul) $3,153,122 (199th) |
Close (30-Jun) $0.091 |
Volume (30-Jun) 50,159,971 |
Shortsold (19-Jun) 392,315,164 (5.25%) (41st) |
|
52w High $2.75 |
52w Low $0.340 |
P/E - |
EPS -0.6 |
IMU released this announcement to the ASX on 13 December 2021, 18:42. The announcement is not marked as price sensitive, and is 5 page(s) in length and 349.99kb in size.
You can view all announcements from IMU and see how they appear on a price chart on the announcements page.
At the date of this announcement, IMU was 2.975% short sold according to ASIC data. It was ranked the 55th most shorted stock on the ASX. It is now ranked as the 41st most shorted stock on the ASX with 5.254% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from IMU | |
|---|---|
| Change of Director's Interest Notice | 30 June 2023, 16:33 |
| HER-Vaxx induced antibodies correlated with tumour reduction | 30 June 2023, 8:40 |
| Imugene PD1-Vaxx patent extended to 2040 | 29 June 2023, 8:39 |
| Change of Director's Interest Notice - PH | 13 December 2021, 18:42 |
| FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX | 13 December 2021, 8:47 |
| FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA | 13 December 2021, 8:47 |
| Appendix 2A | 10 December 2021, 17:31 |
You must be logged in to post a reply.
Imugene 